Coxsackievirus A10 replicon (CV-A10 replicon)

The Coxsackievirus A10 (CV-A10) replicon is a laboratory-engineered subgenomic RNA molecule used as a research tool to study the replication of CV-A10, a significant pathogen in the Enterovirus C genus responsible for hand, foot, and mouth disease (HFMD) (Source: PubMed, PMID: 31433934). The replicon is typically constructed by replacing the structural P1 gene region with a reporter gene, such as luciferase, while retaining the non-structural protein-coding regions (P2 and P3) necessary for RNA replication (Source: Viruses, 2020). This modification allows the replicon to replicate its genome and express viral proteins within a host cell without producing infectious progeny, providing a safer and more efficient platform for high-throughput antiviral screening (Source: Antiviral Research, 2018). The primary therapeutic targets expressed by the replicon include the 3C protease (3Cpro), which is essential for polyprotein processing, and the 3D RNA-dependent RNA polymerase (3Dpol), which is responsible for genome synthesis (Source: Journal of Virology). Drugs like Rupintrivir target the 3Cpro expressed by the replicon to block viral replication, making the replicon system an invaluable asset for identifying and characterizing novel small-molecule inhibitors (Source: NIH/NCBI).

Other names

CVA10 repliconCoxsackievirus A10 subgenomic repliconCV-A10 reporter replicon

Inhibition of viral 3C protease (3Cpro) to prevent polyprotein cleavage, or inhibition of the 3D RNA-dependent RNA polymerase (3Dpol) to terminate viral RNA synthesis.